請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/16281
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 李吉仁(Ji-Ren Lee) | |
dc.contributor.author | Shih-Li Su | en |
dc.contributor.author | 蘇十力 | zh_TW |
dc.date.accessioned | 2021-06-07T18:08:00Z | - |
dc.date.copyright | 2012-08-19 | |
dc.date.issued | 2012 | |
dc.date.submitted | 2012-07-18 | |
dc.identifier.citation | 中文部份
TCOG婦癌工作群編撰小組,2004,婦癌臨床指引,國家衛生研究院 于美德,2002,我國醫藥廣告管理政策探討,元智大學管理研究所未出版之碩士論文,中壢,臺灣。 江孟軒,2010,台灣健保制度下專利到期藥品之競合策略:以抗憂鬱藥品為例,國立台灣大學國際企業研究所未出版之碩士論文 周旭華譯,1998,競爭策略,台北,天下文化。Porter, M. E. 1980. Competitive Strategy, New York, NY: The Free Press. 保蓓中文仿單(衛署菌疫輸字第000856號) 香港HPV疫苗團購優惠宣傳海報,2010,Merck Sharp & Dohme, Hong Kong。 徐梅屏,2003,媒體行銷的奇葩:醫療產業的置入性行銷初探,國立臺灣大學在職碩士專班知識管理組未出版之碩士論文。 許恩得譯,2004,競合策略,台北,台灣培生集團。Brandenburger, A. M. and Nalebuff, B. J. 1996. Co-opetition, New York, NY: The Free Press. 湯澡薰、謝長堯,2006,婦女對人類乳突病毒與子宮頸癌關係的認知,對人類乳突病毒疫苗施打及篩檢的態度,台北,行政院衛生署國民健康局。 董映岑,2010,處方藥之行銷公關策略探討,國立台灣科技大學管理研究所在職管理碩士專班未出版之碩士論文 嘉喜中文仿單(衛署菌疫輸字第000827號) 樊一平,2007,藥品行銷組合策略與醫師處方行為之關聯性研究,國立中正大學管理研究所在職管理碩士專班未出版之碩士論文。 歐玫瑛等,2006,公關能,不能?。台北,滾石文化。 謝幸燕,2005,藥商、醫院與醫師的處方決策:醫療制度與組織面之脈絡分析,台灣社會學刊,第34卷:頁59-114。 謝凱宇、林舒柔譯,2003,現代策略管理,台北:科大文化。Grant, R.M. 2002. Contemporary Strategy Analysis, Oxford, UK: Blackwell Publishing. 英文部份 Baumol, William J., Panzar, John C., and Willig, Robert D. 1982. Contestable Markets and the Theory of Industry Structure. New York, NY: Harcourt Brace Jovanovitch. Coroporate Sales Model Introduction. 2010. Merck Sharp & Dohme, Korea. Garland, Hernandez-Avila, Wheeler, Perez, Harper, Leodolter, Tang, Ferris, Steben, Bryan, Taddeo, Railkar, Esser, Sings, Nelson, Boslego, Sattler, Barr, Koutsky, and Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. 2007. Quadrivalent Vaccine Against Human Papillomavirus to Prevent Anogenital Diseases. New England Journal of Medicine. 356(19):1928-43. GlaxoSmithKline. Annual Report. 2006-2011. IMS Taiwan Pharmaceutical Market Report, 2007-2011 Kalorama Information. 2008. The Vaccines 2008: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry. New York, NY: Heffner, S. Kim JJ and Goldie SJ. 2008. Health and Economic Implications of HPV Vaccination in the United States. New England Journal Medicine. 359(8):821-832. Kols, A, Sherris, J, Herdman, C, and Wittet, S. 2006. Current and Future HPV Vaccines: Promise and Challenges. Seattle, WA. Program for Appropriate Technology in Health (PATH). Koshiol JE, Laurent SA, Pimenta JM. 2004. Rate and Predictors of New Genital Warts Claims and Genital Warts Related Healthcare Utilization Among Privately Insured Patients in the United States. Sexually Transmitted Diseases. 31: 748-752 Kotler, P. and Mindak, W. 1978. Marketing and Public Relations: Should They Be Partners or Rivals?. Journal of Marketing. 42(10): 13–20.。 Koulinska I, Lyons J. 2011. Emerging Vaccines. Infectious Disease Study, Decision Resource. November:70-99 Koutsky, L. 1997. Epidemiology of Genital Human Papillomavirus Infection. The American Journal of Medicine. 102:3-8. Merck & Co. Annual Report. 2006-2011 Pearce II, John A. 2006. How Companies Can Preserve Market Dominance after Patents Expire. Long Range Planning. 39(1): 71-87 Sheridan, C. 2009. Vaccine Market Boosters. Nature Biotechnology. Volume 27, Number 6, June: 499-501 Walboomers JM, Jacobs MV, Manos MM, et al. 1999. Human Papillomavirus Is a Necessary Cause of Invasive Cervical Cancer Worldwide. The Journal of Pathology 189 (1): 12–9 Winer, RL, Lee, S-K, Hughes, JP. 2003. Genital Human Papillomavirus Infection: Incidence and Risk Factors in a Cohort of Female University Students. American Journal of Epidemiol. 157:218–226. World Health Organization. 2006. Human papillomavirus infection and cervical cancer. Available at: http://www.who.int/vaccine_research/diseases/hpv/en/. Accessed January 5, 2006. World Health Organization. 2006. Immunization, vaccines and biologicals: Vaccine research and development. Available at: http://who.int/vaccines/en/hpvrd.shtml. Accessed January 5,2006. 網站部份 Krishan Maggon, 2011, Top 10 Vaccines 2008-2011:http://top10vaccines.wordpress.com/2012/04/29/global-vaccine-market-2010/ MBA智庫百科:LG集團簡介:http://wiki.mbalib.com/zh-tw/LG%E9%9B%86%E5%9B%A2 MBA智庫百科:SK集團簡介:http://wiki.mbalib.com/zh-tw/%E9%9F%A9%E5%9B%BDSK%E9%9B%86%E5%9B%A2 宋豪麟,2012,《生技面面觀─全球篇》從疫苗看全球市況商機,社團法人國家生技醫療產業策進會:http://www.ibmi.org.tw/client/ReportDetail.php?REFDOCTYPID=0lgfj4wgz050jz89&REFDOCID=0lzo3sxt8fxaub91 快驗保公司官方網站:http://www.medifast.com/hk/big5/index.htm 許毓真,2008,全球人用疫苗市場的黃金時期,經濟部ITIS智網:http://www2.itis.org.tw/netreport/NetReport_Detail.aspx?rpno=C054EF713BE5E85A482574C5005DC6FD 陳麗敏,2006,全球疫苗市場分析,經濟部ITIS智網:http://www2.itis.org.tw/netreport/NetReport_Detail.aspx?rpno=53075897586A695A482571FE0014FE5E 愛,從關心HPV開始:HPV是什麼? http://hpvcare.com.tw/whatishpv.html 維基百科:三星集團簡介:http://zh.wikipedia.org/wiki/%E4%B8%89%E6%98%9F%E9%9B%86%E5%9C%98 瑪麗安婦產科:人類乳突病毒(HPV)疫苗接種須知 http://www.marianswoman.org/News/008-HPV.htm | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/16281 | - |
dc.description.abstract | 人類乳突病毒(Human Papillomavirus, HPV)所引起的子宮頸癌現為全世界婦女第二常見的癌症,HPV同時也是生殖器疣、肛門癌、陰莖癌的元兇。這些病症將對病患、家庭以及整體社會帶來沈重的負擔。默沙東藥廠(Merck & Co.)於2006年推出了第一支子宮頸癌疫苗Gardasil(嘉喜),緊接著2008年葛蘭素史克藥廠(GlaxoSmithKline)也推出了Cervarix(保蓓)疫苗。但在台灣,整體HPV疫苗自費市場卻從2008年超過3億新台幣的銷售額,萎縮到2011年只有1.9億。
針對此一問題,本研究採取實證研究,站在主要廠商的角度,規劃可永續發展的競合策略,並提供兼具理論基礎與實務價值的策略建議。我們首先分析台灣HPV疫苗市場概況,以五力模型分析產業結構,並透過產業專家訪談歸納出:兩家廠商的惡性競爭、價格與衛教觀念、疫苗商品特性、以及政府公費為市場萎縮的主要原因。接著我們進一步分析默沙東、GSK兩家公司策略作為,發現廠商現有策略是造成整體市場缺乏成長動力的原因。 據此,我們引用價值網理論建構競合策略。我們提出幾項有效的策略建議,包括:與保險公司合作、嘗試納入一般企業福利、加強衛教觀念推廣、DTC與差異化行銷策略、在地生產策略、與競爭對手合作策略等六種。其中前三者可帶入其他產業之互補者,可行性較高;後三者則因產業條件、法規限制及競爭因素可行性較低。最後,本研究整理了香港以及韓國類似的疫苗策略成功案例,以做為廠商在台灣市場標竿學習的對象。本研究結果期能提供台灣HPV疫苗自費市場廠商規劃具體可行的長期競合策略依據,跳脫以往傳統藥品的經營框架,朝著永續經營的目標邁進。 | zh_TW |
dc.description.abstract | Human Papillomavirus (HPV)-induced cervical cancer is the second most common cancer for women worldwide, and HPV is also the major cause of genital warts, anal and penile cancer. These diseases have brought a heavy burden to patients, families, and the society. MSD launched the first HPV vaccine, Gardasil, in 2006 and followed by GSK, which launched Cervarix in 2008. Despite these new launches, the overall HPV vaccine market in Taiwan had been declining from more than 300 million NTD in 2008 to 190 million in 2011.
The purpose of the present study is to analyze the reasons underlying the market decline and explore the co-opetition strategy that could be undertaken by from the major players for sustainable operations. By taking qualitative, case-based approach, we attempt to submit workable strategic proposal with theoretical supports. First, we overlook the HPV vaccine market in Taiwan by using five-force framework and in-depth interviews. Analytical results show that the cut-throat competition of two major players, the market acceptance of vaccine products, the characteristics of vaccine products, and the tender system of government purchase on vaccine products are four major reasons which cause the market to shrink. Next, we analyzed the existing strategies of these two major players. It indicates that the problem of the shrinking market and declining profits cannot be resolved if companies continue to use current pricing strategies. As a result, taking the analytical concept of value net, we develop a set of co-opetition strategy with six elements: to cooperate with insurance companies, to develop the corporation benefits, to strengthen the attitude and adoption behavior of prevention healthcare, DTC and differential marketing strategy, to localize manufacturing alliance, and to cooperate with competitor. Finally, we provide several successful initiatives held in Hong Kong and Korea in order to build benchmarks for local companies. | en |
dc.description.provenance | Made available in DSpace on 2021-06-07T18:08:00Z (GMT). No. of bitstreams: 1 ntu-101-R98724029-1.pdf: 1935645 bytes, checksum: 408f0d27745e8ee94be80a908cd53953 (MD5) Previous issue date: 2012 | en |
dc.description.tableofcontents | 第一章 緒論 - 1 -
第一節 研究背景與動機 - 1 - 第二節 研究問題 - 3 - 第三節 研究目的 - 4 - 第四節 研究方法 - 4 - 第二章 文獻探討 - 7 - 第一節 五力分析 - 7 - 第二節 競合策略 - 11 - 第三節 醫藥行銷 - 17 - 第三章 HPV疫苗市場分析 - 20 - 第一節 HPV與其相關疾病 - 20 - 第二節 HPV疫苗 - 22 - 第三節 全球HPV疫苗市場 - 24 - 第四節 台灣自費HPV疫苗市場 - 29 - 第五節 產業結構分析 - 33 - 第六節 市場萎縮的衝擊 - 37 - 第四章 HPV疫苗市場廠商之競合策略 - 41 - 第一節 現行廠商競爭行為與策略分析 - 41 - 第二節 價值網模型 - 47 - 第三節 PARTS應用 - 49 - 第四節 競合策略與可行性評估 - 56 - 第五節 可行性評估 - 61 - 第六節 他國疫苗推廣案例 - 63 - 第五章 結論與建議 - 73 - 第一節 研究結論與貢獻 - 73 - 第二節 研究限制與後續研究建議 - 77 - 參考資料 - 79 - | |
dc.language.iso | zh-TW | |
dc.title | 台灣人類乳突病毒疫苗自費市場之競合策略分析 | zh_TW |
dc.title | A Study on the Co-opetition Strategies in the Self-paid HPV Vaccine Market in Taiwan | en |
dc.type | Thesis | |
dc.date.schoolyear | 100-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 陳俊忠,吳相勳 | |
dc.subject.keyword | HPV疫苗產業,價值網,競合策略, | zh_TW |
dc.subject.keyword | HPV Vaccine Market,Value Net,Co-opetition Strategy, | en |
dc.relation.page | 83 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2012-07-18 | |
dc.contributor.author-college | 管理學院 | zh_TW |
dc.contributor.author-dept | 國際企業學研究所 | zh_TW |
顯示於系所單位: | 國際企業學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-101-1.pdf 目前未授權公開取用 | 1.89 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。